Indication · with carbapenem-resistant acinetobacter infections, with positive top-line data

with carbapenem-resistant acinetobacter infections, with positive top-line data FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 1 with carbapenem-resistant acinetobacter infections, with positive top-line data drug. No FDA approvals recorded yet.

Drugs

DrugSponsorModalityDesignations
carbapenemINVA——

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
May 2023Month disclosedcarbapenemINVATopline readoutwith carbapenem-resistant Acinetobacter infections, with positive top-line dataPositiveSEC Form 10-K

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.

Questions

What with carbapenem-resistant acinetobacter infections, with positive top-line data drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.